TECH
Bio-Techne Corp
NASDAQ · Life Sciences Tools & Services
$66.78
+0.92 (+1.40%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.19B | 1.16B | 4.96B | 4.96B | 3.84B |
| Net Income | 71.91M | 62.63M | 316.31M | 349.73M | 285.59M |
| EPS | — | — | — | — | — |
| Profit Margin | 6.0% | 5.7% | 6.4% | 7.1% | 7.4% |
| Rev Growth | +3.3% | +3.3% | -8.3% | -8.8% | +23.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 798.00M | 798.00M | 484.11M | 586.61M | 603.00M |
| Total Equity | 4.43B | 4.43B | 5.40B | 6.41B | 5.49B |
| D/E Ratio | 0.18 | 0.18 | 0.09 | 0.09 | 0.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 129.31M | 118.88M | 705.73M | 713.51M | 532.70M |
| Free Cash Flow | — | — | 205.50M | 309.30M | 255.34M |